Acute Ischemic Stroke Clinical Trial
Official title:
A Prospective, Multi-center and Randomized Controlled Clinical Trial to Assess the Safety and Effectiveness of Tianyi Revascularization Device of in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
NCT number | NCT05496361 |
Other study ID # | CTP-301 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 24, 2021 |
Est. completion date | July 20, 2022 |
Verified date | August 2022 |
Source | Suzhou Zenith Vascular Scitech Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel occlusion in the cerebral circulation.
Status | Completed |
Enrollment | 238 |
Est. completion date | July 20, 2022 |
Est. primary completion date | November 24, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. aged 18-85 years 2. within 8 hours after symptom onset 3. The results showed that the scores of ASPECTS =6, 0<NIHSS<30 , and mRS <2 ; 4. caused by a large vessel occlusion of the anterior circulation (internal carotid artery or the M1 and M2 segments of MCA and the A1 and A2 segments) cerebral artery confirmed by DSA; 5. Signed informed consent. Exclusion Criteria: Clinical exclusion criteria: 1. Patients with epileptic seizure during stroke; 2. Patients with life expectancy less than 90 days; 3. Patients with intracranial hemorrhage or subarachnoid hemorrhage on the same side in recent 3 months; 4. Previous history of intracranial tumor, cerebral arteriovenous malformation or aneurysm without surgical treatment 5. Patients with a history of cerebral infarction or myocardial infarction or uncontrolled serious infectious diseases (such as endocarditis or septicemia) in recent 3 months; 6. Patients with gastrointestinal or urinary tract bleeding in the past three weeks; 7. Patients who have participated in clinical trials of other drugs or devices and have not been withdrawn from the group within the first one months of the screening period of this trial; 8. Patients with serious mental history, heart, liver, lung and kidney failure or other serious diseases; 9. Patients with active bleeding or known bleeding tendency (INR>3.0 or platelet count<40*10^9/L or APTT>50 seconds); 10. The blood glucose which could not be controlled by drugs was less than 2.7 mmol/L or more than 22.2 mmol/L; 11. Patients with hypertension beyond the control of drugs (systolic blood pressure >180 mmHg, or diastolic blood pressure >105 mmHg); 12. Females who are pregnant or in lactation; 13. Patients who are known to be allergic or resistant to contrast agents, anesthetics, anticoagulants, antiplatelet drugs and nickel-titanium; 14. Patients who have undergone major surgical operations in the past month; 15. Other cases with unknown onset time or unsuitable for inclusion in the group judged by researchers;other conditions not suitable for inclusion judged by the researcher; Imaging exclusion criteria 1. Patients with intracerebral hemorrhage confirmed by CT (except for microbleeds. At the discretion of each Investigator); 2. ASPECTS <6 points on head CT; 3. Patients with common carotid artery occlusion who are known or suspected to be chronic occlusion; 4. DSA showed that bilateral carotid system was occluded at the same time; 5. DSA showed (or highly suspected) carotid dissection or arteritis; 6. DSA showed that the vascular route was tortuous, and the device was difficult to reach the target position or recover; 7. Subjects who are not eligible for inclusion after imaging review in the group judged by researchers. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Changhai Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Suzhou Zenith Vascular Scitech Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours | Within 24 hours post-procedure | ||
Other | All causes of mortality at 90 days | at 90 days post-procedure | ||
Other | Occurrence of serious adverse events or adverse events related to device or procedure | at 90 days post-procedure | ||
Other | Occurrence of device defect | at 90 days post-procedure | ||
Primary | Revascularization assessed by digital subtraction angiography of the occluded target vessel to mTICI 2b or 3 at immediate post-procedure | At immediate post-procedure | ||
Secondary | Times to revascularization(From groin puncture to final revascularization result) | At immediate post-procedure | ||
Secondary | NIHSS score at 24h, 7-day or discharge | Within 24 hours,7-day or discharge post-procedure, whichever came first | ||
Secondary | Functional patient outcome at 90 days post-procedure as defined by a modified Rankin Score (mRS) 0-2 | at 90 days post-procedure | ||
Secondary | Device Technical Success | At immediate post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |